We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
23 result(s) found, displaying 1 to 10
-
Prescription medicine registrationActive ingredients: vosoritide.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOXZOGO vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOXZOGO vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe.
-
Designation or determinationPriority review
-
Australian public assessment report (AusPar)AusPAR for Voxzogo (vosoritide) for the treatment of achondroplasia.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALYNZIQ pegvaliase 20 mg/mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALYNZIQ pegvaliase 10 mg/0.5 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALYNZIQ pegvaliase 2.5 mg/0.5 mL solution for injection pre-filled syringe.